These effects could arguably be leveraged in MDS and AML as cytotoxic effects of lenalidomide have been demonstrated to be mediated by CRBN and IKZF1 in AML [56] as well as de-repression of both GPR68 and RCAN1 in MDS [57]. The gene discussed is GPR68; the disease is myelodysplastic syndrome.